Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed what community oncologists should keep in mind when treating patients who are viable...

While tyrosine kinase inhibitors the current standard of care for most patients with CML, investigators may need to look at new options and combinations...

Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with...

  • 1575606789147697154 Profile photo of Madelyn

    Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with #prostatecancer over the past decade. #pcsm https://t.co/wp9L6rrQXY - view on twitter

With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients...

Clinicians use their knowledge of emerging subtypes and biomarkers, which provide a hint at possible outcomes, to select therapy from among the ever-increasing treatment...

Nitin Jain, MD, explains the key takeaways from multiple discussions on acute lymphoblastic leukemia which were presented at the 10th Annual Meeting of the...

For Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical...

A SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system...

With an overall response rate of 50% and greater than 5 months median progression-free survival in patients with first-line metastatic uveal melanoma, darovasertib and...

  • 1575501342734692354 Profile photo of Madelyn

    With an overall response rate of 50% and greater than 5 months median progression-free survival in patients with first-line metastatic uveal #melanoma, #darovasertib and #crizotinib shows a compelling clinical efficacy profile. #melsm https://t.co/luexoaBOJW - view on twitter

The humanized monoclonal antibody JSP191 showed an 100% complete donor chimerism and resulted in no treatment-related adverse events when administered to patients with Fanconi...